Literature DB >> 6429242

Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes.

C Y Wang, W Azzo, A Al-Katib, N Chiorazzi, D M Knowles.   

Abstract

We report in this paper the generation and characterization of three monoclonal antibodies, designated alpha BL1, alpha BL2, and alpha BL3, that recognize distinctive antigens unrelated to complement, Fc, and mouse erythrocyte rosette receptors, which are preferentially expressed on B lymphocytes. alpha BL1 recognizes a heat stable nonimmunoprecipitable antigen, possibly glycolipid in nature. Alpha BL2 recognizes a nonreducible single polypeptide with a m.w. of 68,000 that occasionally co-precipitates with a p29,34 complex of HLA-DR antigens. Alpha BL3 recognizes a nonreducible single polypeptide with a m.w. of 105,000 with an acidic pI point. We demonstrated that BL1 is expressed on fetal liver hematopoietic cells, a small subset (5 to 15%) of Ficoll-Hypaque-separated normal bone marrow cells, and on a subpopulation of nonadherent, non-E rosette-forming cells and granulocytes. BL2 is expressed on fetal liver hematopoietic cells, on 3 to 7% of normal bone marrow cells, and on a majority (40 to 70%) of nonadherent, non-E rosette-forming cells with a distinctive pattern similar to that of HLA-DR. BL3 is expressed on a subpopulation of nonadherent, non-E rosette-forming cells, and on occasional cells in the monocyte-enriched adherent cell population. The peak fluorescence for BL2 is substantially higher than that of BL1 and BL3, indicating higher BL2 antigen density. All three antigens are absent from thymocytes and E rosette-positive T cell fractions obtained from various lymphoid tissues. Cellular distribution of the BL antigens on various well-characterized established hematopoietic cell lines, leukemias, and malignant lymphomas, in conjunction with the results of the in vitro activation and TPA-induction experiments, suggest that BL1 is expressed during early developmental stages of B cell differentiation, whereas BL3 is expressed at the later stages. BL2 expression spans immature and mature stages of B cell differentiation, with the exception of mature plasma cells. The alpha BL antibodies described here should prove to be useful in the investigation of B cell differentiation and in the clinical diagnosis of lymphoid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

2.  An activation antigen on a subpopulation of B lymphocytes identified by the monoclonal antibody CMRF-17.

Authors:  S F Peach; S E Davidson; J L McKenzie; J C Nimmo; D N Hart
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

3.  Surface glycoproteins as markers of the cellular status of B chronic lymphocytic leukaemia lymphocytes.

Authors:  V A Brown; S K Smith; A E Dewar; G Stockdill; A H Maddy
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

Review 4.  Surface antigens associated with human B cell activation.

Authors:  L K Jung
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

5.  Survivin is released from cancer cells via exosomes.

Authors:  Salma Khan; Jessica M S Jutzy; Jonathan R Aspe; Dalmor W McGregor; Jonathan W Neidigh; Nathan R Wall
Journal:  Apoptosis       Date:  2011-01       Impact factor: 4.677

6.  Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.

Authors:  E Weber; H P Lehmann; A G Beck-Sickinger; E J Wawrzynczak; R Waibel; G Folkers; R A Stahel
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle.

Authors:  D Figarella-Branger; H Moreau; J F Pellissier; N Bianco; G Rougon
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  SIg-E- ("null-cell") non-Hodgkin's lymphomas. Multiparametric determination of their B- or T-cell lineage.

Authors:  D M Knowles; L Dodson; J S Burke; J M Wang; F Bonetti; P G Pelicci; F Flug; R Dalla-Favera; C Y Wang
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

9.  Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

Authors:  Maria Rehnberg; Sylvie Amu; Andrej Tarkowski; Maria I Bokarewa; Mikael Brisslert
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

10.  Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential.

Authors:  S Khan; J R Aspe; M G Asumen; F Almaguel; O Odumosu; S Acevedo-Martinez; M De Leon; W H R Langridge; N R Wall
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.